Century Therapeutics Reports on Shareholder Vote Matters

TL;DR

Century Therapeutics held a shareholder vote on June 20th. Details TBD.

AI Summary

Century Therapeutics, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders as of June 20, 2024. The filing does not contain specific details about the vote outcomes or the matters voted upon, only that such a submission occurred.

Why It Matters

This filing indicates that Century Therapeutics held a shareholder vote, which could pertain to significant corporate actions or governance changes that may impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial information or material events that would immediately impact the company's risk profile.

Key Players & Entities

• Century Therapeutics, Inc. (company) — Registrant
• June 20, 2024 (date) — Date of earliest event reported
• June 24, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select

Filing Documents

• tm2417806d1_8k.htm (8-K) — 34KB
• 0001104659-24-074339.txt ( ) — 206KB
• ipsc-20240620.xsd (EX-101.SCH) — 3KB
• ipsc-20240620_lab.xml (EX-101.LAB) — 33KB
• ipsc-20240620_pre.xml (EX-101.PRE) — 22KB
• tm2417806d1_8k_htm.xml (XML) — 4KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 20, 2024, Century Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 24, 2024, the record date for the Annual Meeting, there were 82,847,375 outstanding shares of the Company's common stock. The Annual Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities Exchange Commission on April 26, 2024. (a) Proposal 1 - Election of Class III Directors . Each of Kimberly Blackwell, M.D., Joseph Jimenez and Brent Pfeiffenberger, Pharm.D. were elected to the Company's Board of Directors to serve as Class III directors until the 2027 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name For Against Abstentions Broker Non-Votes Kimberly Blackwell, M.D. 59,931,468 0 6,014,484 7,395,050 Joseph Jimenez 64,376,622 0 1,569,330 7,395,050 Brent Pfeiffenberger, Pharm.D. 65,728,988 0 216,964 7,395,050 (b) Proposal 2 - Ratification of Independent Registered Public Accountant . The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2024 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 72,250,603 1,065,984 24,413 0 (c) Proposal 3 – Approval of the Certificate of Amendment . The Amendment to the Company's Second Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") to limit the liability of certain of the Company's officers as permitted by recent amendments to Delaware law was approved, as follows: For Against Abstentions Broke

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: June 24, 2024

View Full Filing

View this 8-K filing on SEC EDGAR